019170.KS Shinpoong Pharmaceutical Co.,Ltd Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
01:00
Oct 07
Oct 07
815 Money Talk
Shinpoong: avoid chasing epidemic momentum and profit-taking risk.
Lee expects that Shinpoong and the named Korean epidemic-theme group may face profit-taking after the prior rally, following weakness in US vaccine shares. Further suspected or confirmed cases, or uncertainty about Russian disclosures, could still extend speculative momentum. She expects little available market flow into this theme; the AVOID is a current catalyst and entry-risk assessment, not an inferred short or a claim that Shinpoong has Moderna's vaccine product profile.
019170.KS
Shinpoong Pharmaceutical Co.,Ltd
Avoid
—
—
00:54
Apr 17
Apr 17
815 Money Talk
Vaccine stocks get policy support
Korea's National Growth Fund will support bio-vaccine and phase 3 clinical programs, reviving vaccine names such as Shin Poong Pharm, Jin Won Life Sciences, and Bioneer.
019170.KS
Shinpoong Pharmaceutical Co.,Ltd
Long
1ST
—
—
About 019170.KS Investor Commentary
Across the available history and selected sources, Buzzberg tracks 019170.KS (Shinpoong Pharmaceutical Co.,Ltd) across 1 sources: 1 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 50% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: Lee Ju-yeon, Oh Hyun-jin.